Press Releases
Measles Oncolytic Virus as an Immunotherapy for Recurrent/Refractory Pediatric Medulloblastoma and Atypical Teratoid/Rhabdoid Tumor: Results from PNOC005
PNOC005 is a phase I clinical trial investigating the safety and tolerability of intratumoral or intrathecal administration of oncolytic measles virus (MV-NIS) in children and young adults with recurrent medulloblastoma or ATRT.
Journal of Clinical Investigations Just a spoonful of metformin helps the medicine go down
Diffuse intrinsic pontine glioma (DIPG) is a devastating brain tumor with a need for novel therapies. So far, monotherapies have failed to prolong survival for these patients, and combinatorial strategies have often shown severe, dose-limiting toxicities.
Neuro-Oncology Rational combination platform trial design for children and young adults with diffuse midline glioma
Diffuse midline glioma (DMG) is a devastating pediatric brain tumor unresponsive to hundreds of clinical trials. Approximately 80% of DMGs harbor H3K27M oncohistones, which reprogram the epigenome to increase the metabolic profile of the tumor cells.
Journal of Clinical Oncology PNOC001: Phase II Study of Everolimus For Recurrent or Progressive Low-Grade Gliomas in Children
The PNOC001 phase II single-arm trial sought to estimate progression-free survival (PFS) associated with everolimus therapy for progressive/recurrent pediatric low-grade glioma (pLGG) on the basis of phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway activation as measured by phosphorylated-ribosomal protein S6 and to identify prognostic and predictive biomarkers.
American Association for Cancer Research Journal ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
Diffuse midline gliomas (DMG), including diffuse intrinsic pontine gliomas (DIPG), are the most lethal of childhood cancers.
Neoplasia Journal Machine Learning Identifies Subgroups of Pediatric Low-grade Gliomas that Correlate with Key Molecular Markers
Despite advancements in molecular and histopathologic characterization of pediatric low-grade gliomas (pLGGs), there remains significant phenotypic heterogeneity among tumors with similar categorizations.
Pediatric Neurosurgery Advances and Clinical Trials Update in the Treatment of Diffuse Intrinsic Pontine Gliomas
Diffuse intrinsic pontine gliomas (DIPGs) are high-grade gliomas (HGGs) that occur primarily in children, and represent a leading cause of death in pediatric patients with brain tumors with a median overall survival of only 8–11 months.
European Journal of Cancer Real-time drug testing of paediatric diffuse midline glioma: The Zurich DIPG/DMG centre experience
Diffuse Midline Glioma (DMG) which includes Diffuse Intrinsic Pontine Glioma (DIPG) is an infiltrative tumor of the midline structures of the central nervous system that demonstrates an aggressive pattern of growth and has no known curative treatment.
Neoplasia Journal Interdisciplinary care of children with diffuse midline glioma
Diffuse Midline Glioma (DMG) which includes Diffuse Intrinsic Pontine Glioma (DIPG) is an infiltrative tumor of the midline structures of the central nervous system that demonstrates an aggressive pattern of growth and has no known curative treatment.
Clinical Cancer Research Upfront Biology-Guided Therapy in Diffuse Intrinsic Pontine Glioma: Therapeutic, Molecular, and Biomarker Outcomes from PNOC003
PNOC003 is a multicenter precision medicine trial for children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
Neuro-Oncology DIPG-31 Prognostic and predictive biomarkers for H3K27M-altered diffuse intrinsic pontine glioma from PNOC003
Diffuse intrinsic pontine glioma (DIPG) is a fatal brain tumor. Herein, we report on novel prognostic and predictive genomic biomarkers identified in PNOC003, a multi-center precision medicine trial for children and young adults diagnosed with DIPG.
Journal of Neurosurgery Liquid biopsy for diffuse intrinsic pontine glioma: an update
Diffuse intrinsic pontine glioma (DIPG), otherwise known as diffuse midline glioma with H3K27M mutation, is a devastating brainstem glioma without a cure. Efforts are currently underway to better optimize molecular diagnoses through biological sampling, which today remains largely limited to surgical biopsy sampling.
International Journal of Cancer A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: A report from PNOC
This clinical trial evaluated whether whole exome sequencing (WES) and RNA sequencing (RNAseq) of paired normal and tumor tissues could be incorporated into a personalized treatment plan for newly diagnosed patients (<25 years of age) with diffuse intrinsic pontine glioma (DIPG).
DIPG-76 PNOC-003: trial for children with diffuse intrinsic pontine glioma: preliminary experience with multi-agent personalized therapy recommendations
New therapies for children with diffuse intrinsic pontine glioma (DIPG) are greatly needed.